🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Cue Biopharma, Inc. (CUE)
NASDAQ: CUE · Real-Time Price · USD
4.500
-0.260 (-5.46%)
At close: Nov 19, 2026, 4:00 PM EST
4.240
-0.260 (-5.78%)
After-hours: Nov 19, 2026, 7:59 PM EST

Cue Biopharma Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
35.6427.479.295.491.2514.94
Revenue Growth
402.01%195.75%69.16%340.96%-91.67%373.68%
Cost of Revenue
15.8334.8432.940.835.341.35
Gross Profit
19.81-7.38-23.61-35.31-34.05-26.41
Selling, General & Admin
84.719.1417.9916.6819.4517.31
Research & Development
72.92-----
Operating Expenses
157.6219.1417.9916.6819.4517.31
Operating Income
-137.81-26.52-41.59-51.99-53.5-43.71
Interest Expense
-0.12-0.36-0.8-1.25-0.71-
Interest & Investment Income
1.040.811.622.660.930.05
Other Non Operating Income (Expenses)
-69.42-----
EBT Excluding Unusual Items
-206.32-26.07-40.77-50.58-53.29-43.67
Gain (Loss) on Sale of Assets
0.02-0.030.09-0.160.28-
Pretax Income
-206.18-26.1-40.67-50.73-53.01-43.67
Income Tax Expense
0.50.5---0.5
Net Income
-206.68-26.6-40.67-50.73-53.01-44.16
Net Income to Common
-206.68-26.6-40.67-50.73-53.01-44.16
Net Income Growth
------
Shares Outstanding (Basic)
632211
Shares Outstanding (Diluted)
632211
Shares Change
120.66%68.18%23.11%28.35%13.95%9.05%
EPS (Basic)
-32.58-8.42-21.66-33.26-44.61-42.35
EPS (Diluted)
-32.58-8.42-21.66-33.26-44.61-42.35
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-51.23-21.86-36.4-39.96-41.98-39.75
Free Cash Flow Per Share
-8.07-6.92-19.38-26.20-35.33-38.12
Gross Margin
55.58%-26.86%-254.21%---176.73%
Operating Margin
-386.69%-96.56%-447.86%-947.03%-4297.35%-292.56%
Profit Margin
-579.93%-96.85%-437.97%-924.10%-4257.83%-295.56%
Free Cash Flow Margin
-143.74%-79.60%-391.89%-727.89%-3371.65%-266.04%
EBITDA
-136.5-25.56-41.2-51.44-52.58-42.45
EBITDA Margin
--93.07%----284.14%
D&A For EBITDA
1.310.960.40.560.921.26
EBIT
-137.81-26.52-41.59-51.99-53.5-43.71
EBIT Margin
--96.56%----292.56%
SEC Filings: 10-K · 10-Q